Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SND1** is Shouzu Ning No. 1 formula, an investigational traditional Chinese medicine formula evaluated for treatment of grade 2 vascular endothelial growth factor receptor tyrosine kinase inhibitor-induced hand-foot skin reaction in patients with advanced solid tumors presenting with the traditional Chinese medicine toxic-heat syndrome pattern. A multicenter, randomized, double-blind, placebo-controlled ChiCTR study sponsored by The First Affiliated Hospital of Zhejiang Chinese Medical University was registered in September 2023, but the registry identifies the study as canceled by the investigator. The formula's individual ingredients, dosage form, route, and molecular mechanism were not specified in the public registry record. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=203565))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SND1.